Solventum Corporation (NYSE:SOLV) Shares Sold by Trust Co. of Vermont

Trust Co. of Vermont lowered its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 84.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,477 shares of the company's stock after selling 13,244 shares during the quarter. Trust Co. of Vermont's holdings in Solventum were worth $188,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in SOLV. Clarity Asset Management Inc. bought a new stake in shares of Solventum during the 4th quarter worth approximately $25,000. Raiffeisen Bank International AG bought a new stake in shares of Solventum during the fourth quarter worth $29,000. Colonial Trust Co SC lifted its position in shares of Solventum by 240.7% during the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company's stock worth $34,000 after purchasing an additional 361 shares during the last quarter. Banque Transatlantique SA purchased a new stake in shares of Solventum during the fourth quarter valued at $42,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Solventum by 48.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company's stock worth $45,000 after purchasing an additional 223 shares during the last quarter.

Solventum Stock Performance

Solventum stock traded up $0.22 during mid-day trading on Monday, reaching $75.68. 39,009 shares of the company traded hands, compared to its average volume of 1,125,075. Solventum Corporation has a fifty-two week low of $47.16 and a fifty-two week high of $100.00. The company has a market capitalization of $13.09 billion, a price-to-earnings ratio of 35.06, a price-to-earnings-growth ratio of 1.93 and a beta of 0.54. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85. The firm's fifty day moving average is $71.48 and its two-hundred day moving average is $71.89.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.19 by $0.15. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. Solventum had a return on equity of 31.01% and a net margin of 4.55%. The business's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.08 EPS. On average, equities research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SOLV shares. Mizuho lifted their target price on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd. Morgan Stanley upped their target price on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group lifted their target price on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. KeyCorp started coverage on shares of Solventum in a report on Friday, June 6th. They issued a "sector weight" rating on the stock. Finally, Piper Sandler upgraded shares of Solventum from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $78.00 to $87.00 in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Solventum has a consensus rating of "Hold" and an average price target of $80.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.